首页> 外文OA文献 >Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran

【2h】

Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran

机译：伊朗对具有高滴度抑制剂的血友病A的免疫耐受诱导治疗与重组因子VII按需治疗的成本-效用分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Rasekh, Hamid Reza; Imani, Ali; Karimi, Mehran; Golestani, Mina;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种 {"code":"en","name":"English","id":9}
中图分类

相似文献

外文文献
中文文献
专利

1. Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran [J] . Hamid Reza Rasekh, Ali Imani, Mehran Karimi, ClinicoEconomics and Outcomes Research . 2011,第3期

机译：伊朗对具有高滴度抑制剂的血友病A的免疫耐受诱导疗法与重组因子VII按需治疗的成本-效用分析
2. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy [J] . Peter Kubisz, Ivana Plamenova, Pavol Holly, Medical science monitor : . 2009,第4期

机译：先天性血友病和高滴度凝血因子VIII抑制剂的患者使用高剂量凝血因子VIII和静脉内免疫球蛋白成功诱导免疫耐受，尽管预后不良
3. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment [J] . Earnshaw S. R., Graham C. N., McDade C. L., Haemophilia: the official journal of the World Federation of Hemophilia . 2015,第3期

机译：VIII因子同种抗体抑制剂：免疫耐受诱导与预防和旁路治疗按需的成本分析
4. Course of a severe Hemophilia A. Successful Immyne Tolerance Therapy (ITT) ten Years after Inhibitor Dewelopment [C] . A. Grunske, E. Holfeld, D, Hemophilie-Symposion . 2003

机译：严重的血友病A.抑制剂发育后的成功免疫耐受治疗（ITT）十年
5. Phosphatidylserine mediated immune tolerance induction towards factor VIII (FVIII) for hemophilia therapy: Mechanisms and strategies involved [D] . Ramakrishnan, Radha 2016

机译：血友病治疗中磷脂酰丝氨酸介导的针对因子VIII（FVIII）的免疫耐受诱导：涉及的机制和策略
6. Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran [O] . Hamid Reza Rasekh, Ali Imani, Mehran Karimi, 2011

机译：伊朗对具有高滴度抑制剂的血友病A的免疫耐受诱导治疗与重组因子VII按需治疗的成本-效用分析
7. PSY17 Cost-Utility Analysis of Immune Tolerance Induction (ITI) Therapy Versus On-Demand Treatment With Recombinant FVII (rFVIIa) for Hemophilia A With High Titer Inhibitors in Iran [O] . Imani A., Rasekh H., Golestani M. 2012

机译：PSY17免疫耐受诱导（ITI）治疗与按需治疗联合FVII（rFVIIa）治疗伊朗具有高滴度抑制剂的A型血友病的成本-效用分析

Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran

著录项

引文网络

相似文献

相关主题

期刊订阅